These results demonstrate that the CRISPR-Trap system achieves adequate selection of BCR/ABL null cells, limits the residual unedited events with oncogenic potential and bestows a long-term therapeutic effect in a CML mouse model. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.